A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
Adenocarcinoma of the Rectum|Locally Advanced Rectal Adenocarcinoma|Rectal Adenocarcinoma|HER2 Positive Rectal Adenocarcinoma|Rectal Cancer
DRUG: Trastuzumab|DRUG: Tucatinib
Clinical complete response of study participants, The primary objective of this trial is to determine the clinical complete response rate after the completion of initial neoadjuvant tucatinib and trastuzumab followed by standard of care induction chemotherapy (assessed around week 21 Â± 4 weeks) in subjects with HER2-positive, RAS wild-type locally advanced rectal adenocarcinoma, 21 +/- 4 weeks
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.